Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for advanced liver cancer in major trial

NCT ID NCT04523493

Ongoing Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Dec 12, 2025 · Last updated Apr 25, 2026 · Updated 19 times

Summary

This study tests whether adding the immunotherapy drug toripalimab to the standard targeted therapy lenvatinib helps people with advanced liver cancer live longer. About 530 adults with liver cancer that cannot be treated with surgery will receive either the combination or lenvatinib alone. The main goal is to see if the combination improves overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • A.O.U. Citta della Salute e della Scienza di Torino

    Tortona, Italy

  • AOUI Verona - Policlinico "G.B. Rossi" di Borgo Roma

    Verona, 37134, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, 56126, Italy

  • Centrum Medyczne Pratia Poznań

    Skórzewo, 60-185, Poland

  • Communal Enterprise Volyn Regional Clinical Hospital of Volyn Regional Council

    Lutsk, 43018, Ukraine

  • Communal Non-Profit Institution of Kharkiv Regional Council Regional Clinical Specialized Dispensary of Radiation Protection of Population

    Kharkiv, 61166, Ukraine

  • Communal Non-commercial Enterprise City Clinical Hospital #4 of Dnipro City Council, Department of Chemotherapy

    Dnipro, 49102, Ukraine

  • Communal Non-commercial Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Department of General Surgery

    Odesa, 65025, Ukraine

  • Communal Non-commercial Enterprise Zaporizhzhia Regional Antitumor Center of Zaporizhzhia Regional Council

    Zaporizhzhia, 69040, Ukraine

  • Communal Non-commercial Enterprise of Sumy Regional Council, Sumy Regional Clinical Oncological Dispensar

    Sumy, 40022, Ukraine

  • Communal Non-profit Enterprise "Regional Center of Oncology", Department of Abdominal Organs Oncosurgery

    Kharkiv, 61070, Ukraine

  • Copernicus Podmiot Leczniczy sp. z o.o., Wojewodzkie Centrum Onkologii, Oddzial Onkologii Klinicznej/Chemioterapii

    Gdansk, 80-219, Poland

  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico,Oncologia Medica

    Milan, 20122, Italy

  • ID Clinic

    Mysłowice, 41-400, Poland

  • IRCCS Fondazione Giovanni Pascale, Istituto Nazionale Dei Tumori

    Naples, 80131, Italy

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Klinika Onkologii i Radioterapii

    Warsaw, 02-034, Poland

  • National Cancer Centre Singapore

    Singapore, 168583, Singapore

  • PRATIA MCM Kraków, ul. Pana Tadeusza 2,

    Krakow, 30-727, Poland

  • Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command

    Nanjing, Jiangsu, 21000, China

  • State Inst. O.O.Shalimov Nat. scientific certer of Surgery and Transplantology of Nat. Academy of Med.Sciences of Ukraine, Dep.of Oncology

    Kyiv, 03126, Ukraine

  • Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie, Oddzial Dzienny Chemioterapii

    Koszalin, 75-581, Poland

  • Wielkopolskie Centrum Onkologii, Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dziennym i Izbą Przyjęć

    Poznan, 61-866, Poland

Conditions

Explore the condition pages connected to this study.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)